B cells

[Proceedings of the National Academy of Sciences of the United States of America] Researchers conducted a comprehensive analysis of genome-wide DNA methylation patterns in four peripheral immune cell populations isolated from 29 multiple sclerosis patients at clinical disease onset and 24 healthy controls.

[Molecular Cancer] CRISPR/Cas9 approaches were used to generate stem cell leukemia/lymphoma syndrome cells null for Interleukin receptor associated kinase 1 and interferon gamma which were introduced into syngeneic hosts through tail vein injection.

[CoImmune, Inc.] CoImmune, Inc. announced that results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor modified cytokine induced killer cell platform, demonstrated sustained responses in pediatric and adult patients with B-cell acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic stem cell transplantation.

[Nature Communications] The authors demonstrated that lymphoid-restricted mutant IL7R, expressed at physiological levels in conditional knock-in mice, established a pre-leukemic stage in which B cell precursors displayed self-renewal ability, initiating leukemia resembling PAX5 P80R or Ph-like human B-acute lymphoblastic leukemia.

[Mustang Bio, Inc.] Mustang Bio, Inc. announced updated data from the ongoing Phase I/II clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

[New England Journal of Medicine] In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care.